Ana Villar

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 522 citations · Full text

Inbuild Trial, Parallel-group Trial, Advanced Lung Disease +5

Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study

Ferrán Morell, Ana Villar, María-Ángeles Montero et al. · The Lancet Respiratory Medicine · 2013 · 374 citations

Allergy, Inflammatory Lung Disease, Advanced Lung Disease +7

Diagnosis and Evaluation of Hypersensitivity Pneumonitis

Evans R. Fernández Pérez, William D. Travis, David A. Lynch et al. · CHEST Journal · 2021 · 226 citations · Full text

Drug Hypersensitivity, Allergy, Autoimmune Disease +8

Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven^®) in children vs. adults with haemophilia A

Ana Villar, S Aronis, Massimo Morfini et al. · Haemophilia · 2004 · 147 citations

Global warming vs. climate change, taxes vs. prices: Does word choice matter?

Ana Villar, Jon A. Krosnick · Climatic Change · 2010 · 127 citations

Economics, Public Policy, Carbon Emission Trading +10